ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics.
The company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
ImmuPharma's lead program, Lupuzor™, is a first-in-class autophagy immunomodulator for the treatment of lupus and preclinical analysis suggests therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.